Industry leaders applaud CVS zero co-pay diabetes drug access

CVS is answering the call to decrease the cost burden of diabetes medications on patients

CVS is answering the call to decrease the cost burden of diabetes medications on patients with a new plan that eliminates co-pays, and industry leaders committed to the social contract are applauding the news as a step in the right direction.

On Wednesday, CVS Health Corp. (NYSE:CVS) announced the new RxZERO

Read the full 503 word article

How to gain access

Continue reading with a
two-week free trial.